Vaishali Pharma [VAISHALI] vs Aarey Drugs [AAREYDRUGS] Detailed Stock Comparison
Vaishali Pharma
NSE
Loading...
Aarey Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Vaishali Pharma wins in 6 metrics, Aarey Drugs wins in 12 metrics, with 0 ties. Aarey Drugs appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Vaishali Pharma | Aarey Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 214.50 | 46.82 | Aarey Drugs |
| Price-to-Book Ratio | 2.65 | 11.36 | Vaishali Pharma |
| Debt-to-Equity Ratio | 18.98 | 25.17 | Vaishali Pharma |
| PEG Ratio | -2.41 | -2.10 | Vaishali Pharma |
| EV/EBITDA | 2,027.23 | 713.02 | Aarey Drugs |
| Profit Margin (TTM) | 0.83% | 0.85% | Aarey Drugs |
| Operating Margin (TTM) | -18.32% | -3.18% | Aarey Drugs |
| Return on Equity | 1.52% | 2.97% | Aarey Drugs |
| Return on Assets (TTM) | -0.26% | 0.07% | Aarey Drugs |
| Free Cash Flow (TTM) | $6.96M | $44.49M | Aarey Drugs |
| 1-Year Return | -20.18% | 35.06% | Aarey Drugs |
| Price-to-Sales Ratio (TTM) | 1.67 | 0.40 | Aarey Drugs |
| Enterprise Value | $1.82B | $16.05B | Aarey Drugs |
| EV/Revenue Ratio | 1.84 | 3.39 | Vaishali Pharma |
| Gross Profit Margin (TTM) | 14.97% | -1.00% | Vaishali Pharma |
| Revenue per Share (TTM) | $7 | $169 | Aarey Drugs |
| Earnings per Share (Diluted) | $-1.55 | $1.43 | Aarey Drugs |
| Beta (Stock Volatility) | 0.25 | 0.47 | Vaishali Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Vaishali Pharma vs Aarey Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vaishali Pharma | -1.97% | 2.50% | 10.34% | 2.25% | -29.09% | -28.73% |
| Aarey Drugs | 2.78% | 1.87% | -3.47% | 24.67% | 37.45% | 16.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vaishali Pharma | -20.18% | 43.18% | 202.38% | 200.24% | 200.24% | 200.24% |
| Aarey Drugs | 35.06% | 90.74% | 54.44% | 54.44% | 54.44% | 54.44% |
Performance & Financial Health Analysis: Vaishali Pharma vs Aarey Drugs
| Metric | VAISHALI | AAREYDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.66B | ₹1.90B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 361,637 | 18,379 |
| 90 Day Avg. Volume | 622,346 | 69,873 |
| Last Close | ₹12.45 | ₹68.81 |
| 52 Week Range | ₹10.30 - ₹24.91 | ₹32.85 - ₹74.80 |
| % from 52W High | -50.02% | -8.01% |
| All-Time High | ₹24.91 (Oct 14, 2024) | ₹74.80 (Sep 02, 2024) |
| % from All-Time High | -50.02% | -8.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | -0.49% |
| Quarterly Earnings Growth | 0.00% | -0.78% |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.01% |
| Operating Margin (TTM) | -0.18% | -0.03% |
| Return on Equity (TTM) | 0.02% | 0.03% |
| Debt to Equity (MRQ) | 18.98 | 25.17 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹4.79 | ₹5.89 |
| Cash per Share (MRQ) | ₹0.14 | ₹0.14 |
| Operating Cash Flow (TTM) | ₹-180,383,008 | ₹96.53M |
| Levered Free Cash Flow (TTM) | ₹-217,039,120 | ₹-103,436,624 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Vaishali Pharma vs Aarey Drugs
| Metric | VAISHALI | AAREYDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 214.50 | 46.82 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -2.41 | -2.10 |
| Price to Sales (TTM) | 1.67 | 0.40 |
| Price to Book (MRQ) | 2.65 | 11.36 |
| Market Capitalization | ||
| Market Capitalization | ₹1.66B | ₹1.90B |
| Enterprise Value | ₹1.82B | ₹16.05B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.84 | 3.39 |
| Enterprise to EBITDA | 2,027.23 | 713.02 |
| Risk & Other Metrics | ||
| Beta | 0.25 | 0.47 |
| Book Value per Share (MRQ) | ₹4.79 | ₹5.89 |
Financial Statements Comparison: Vaishali Pharma vs Aarey Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VAISHALI | AAREYDRUGS |
|---|---|---|
| Revenue/Sales | ₹279.14M | ₹1.08B |
| Cost of Goods Sold | ₹237.35M | ₹1.09B |
| Gross Profit | ₹41.79M | ₹-10.77M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹12.44M | ₹-52.60M |
| EBITDA | ₹24.35M | ₹26.86M |
| Pre-Tax Income | ₹19.28M | ₹16.25M |
| Income Tax | ₹4.85M | ₹11.55M |
| Net Income (Profit) | ₹14.43M | ₹4.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VAISHALI | AAREYDRUGS |
|---|---|---|
| Cash & Equivalents | ₹10.21M | ₹14.73M |
| Total Current Assets | ₹983.93M | ₹2.13B |
| Total Current Liabilities | ₹329.65M | ₹968.80M |
| Long-Term Debt | ₹30.20M | ₹19.87M |
| Total Shareholders Equity | ₹677.63M | ₹1.38B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹13.10M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VAISHALI | AAREYDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VAISHALI | AAREYDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 361,637 | 18,379 |
| Average Daily Volume (90 Day) | 622,346 | 69,873 |
| Shares Outstanding | 107.19M | 27.95M |
| Float Shares | 74.88M | 108.10M |
| % Held by Insiders | N/A | 0.53% |
| % Held by Institutions | N/A | 0.02% |
Dividend Analysis & Yield Comparison: Vaishali Pharma vs Aarey Drugs
| Metric | VAISHALI | AAREYDRUGS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |